ogenous arachidonic acid. Addition of 50 Atg of arachidonate to PRP caused complete aggregation and release of 8 AiM ADP, and high concentrations of arachidonate caused no further ADP release (data not shown). As evidence that the platelets were not lysed by the arachidonate, subsequent lysis with Triton caused the release of a total of 20 IAM ADP. Pretreatment of PRP with PGH3 (100 ng) inhibited aggregation and ADP release.
Thromboxane A2 formation was monitored directly by measuring the rabbit aorta contractile activity generated in PRP by exogenous arachidonate or by thrombin. Thrombin was used to liberate endogenous fatty acid from platelet phospholipids. PGH3 (0.1-2 IiM), PGI2 (0.1-2 ,uM), PGH1 (up to 5 ,uM), and dibutyryl cyclic AMP (up to 5 mM) did not alter the contractile activity formed by exogenous arachidonate (0.7 mM) iti PRP (data not shown). However, very low levels of PGH3 (0.3-0. 5 ,uM) or PGI2 (0.1 1iM) inhibited arachidonate-induced PRP aggregation. In contrast, a 50% decrease in formation of contractile activity was induced by thrombin (10 units) in PRP preincubated with PGH3 (0.4-0.7 ,uM), PGI2 (0.3-0.6,uM), or dibutyryl cyclic AMP (5 mM).
Both [14C] eicosapentaenoate and [14C]arachidonate were readily and similarly acylated into phospholipids when incubated with human platelets (Fig. 4 A and E). In addition, deacylation by thrombin or an ionophore (A-23187) of separately prelabeled platelets released comparable amounts of [14C]-arachidonate or [14C]eicosapentaenoate, respectively (Fig. 4 B and F). Pretreatment of the arachidonate-labeled platelets with PGH3 ( Fig. 4C) , PGI2 (Fig. 4D) , or PGH1 (100 ng) markedly decreased the release of fatty acid and abolished the thromboxane formation. There was no increase in fatty acid release over basal levels when thrombin was added to labeled platelets treated with PGH3 or PGI2 (Fig. 4 C and D) .
Competition of Eicosapentaenoate with Arachidonate for Platelet Cyclooxygenase. Unlabeled eicosapentaenoic acid and ["4C]arachidonate were mixed in varying ratios and the reaction was initiated by the addition of washed platelets. The eicosapentaenoate effectively competed with arachidonate such that a 1:1 mixture of the fatty acids resulted in a 50% inhibition of formation of thromboxane B2 and 12-hydroxyeicosatetraenoic and hydroxyheptadecatrienoic acids and block of arachidonic destruction (Fig. 5A ). On the other hand, the eicosapentaenoate was a much poorer substrate for platelet cyclooxygenase, being converted only one-eighth as efficiently as arachidonate to thromboxane (Fig. SB 4 B and F). Pretreatment of the arachidonate-labeled platelets with PGH3 (Fig. 4C) , PGI2 (Fig. 4D) , or PGH1 (100 ng) markedly decreased the release of fatty acid and abolished the thromboxane formation. There was no increase in fatty acid release over basal levels when thrombin was added to labeled platelets treated with PGH3 or PGI2 (Fig. 4 C and D) .
Competition of Eicosapentaenoate with Arachidonate for Platelet Cyclooxygenase. Unlabeled eicosapentaenoic acid and ["4C]arachidonate were mixed in varying ratios and the reaction was initiated by the addition of washed platelets. The eicosapentaenoate effectively competed with arachidonate such that a 1:1 mixture of the fatty acids resulted in a 50% inhibition of formation of thromboxane B2 and 12-hydroxyeicosatetraenoic and hydroxyheptadecatrienoic acids and block of arachidonic destruction (Fig. 5A) . On the other hand, the eicosapentaenoate was a much poorer substrate for platelet cyclooxygenase, being converted only one-eighth as efficiently as arachidonate to thromboxane (Fig. SB (1) . The 3-series endoperoxides were then enzymatically converted by platelet microsomes into a potent labile vasoconstrictor that was presumed to be thromboxane A3 (1, 2) . In addition, application of purified PGH2 (produced from arachidonic acid) or PGH3 to isolated spiral strips of bovine coronary artery caused a transient relaxation, whereas PGHI (produced by 8,11,14-eicosatrienoic acid) contracted the coronary strip (3). The primary product generated by bovine coronary arteries or by isolated perfused rabbit hearts from ['4C]arachidonic acid was 6-keto-PGF1,, (4) (5) (6) , the stable end product formed from prostacyclin (PGI2) ( 7) whereas [14C]eicosatrienoic acid was only converted to PGEI (4, 8) .
These results indicated that the A5 double bond of PG endoperoxides is required for prostacyclin synthesis. Thus, PGH2 is the precursor of PGI2 and its stable aqueous end product 6-keto-PGF1,,, and PGH3 which is an active coronary relaxant was presumably converted to PGI3 and ultimately degraded to its presumed end product A7-6-keto-PGF1,,. However (10) .
[14C]PGH3 was enzymatically synthesized (7-min incubation) and purified as described (1, 11) . 15-Hydroperoxyarachidonic acid, an in vitro prostacyclin synthetase inhibitor (12) , was synthesized with soybean lipoxygenase (13) . Bovine aorta microsomes (BAM) were used as the source of prostacyclin synthetase and were prepared from freshly dissected vessels as described (5) . Aspirin-treated platelet microsomes (APM) were employed as the source of thromboxane synthetase and prepared as previously described (1).
Vascular Smooth Muscle Bioassay. The bovine coronary artery and rabbit thoracic aorta assay tissues were hung in a vertical superfusion cascade and continuously bathed with Krebs-Henseleit solution (95% 02/5% CO2) at 10 ml/min as described (14) (15) (16) .
Platelet Aggregation. Citrated human PRP or washed platelets were prepared as described (17) .
Prostacyclin and Thromboxane Generation. The endoperoxide (PGH2 or PGH3) in acetone was dried in a stream of N2 and resuspended in 25 ,ul of phosphate buffer (50 mM, pH Abbreviations: PG, prostaglandin; PRP, platelet-rich plasma; BAM, bovine aorta microsomes; APM, aspirin-treated platelet microsomes.
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Proc. Natl. Acad. Sci. USA 76 (1979) 945 7.4). Twenty microliters (80 jig of protein) of BAM was added to the endoperoxides and incubated for 1 min at roomi temperature.
Twenty-five microliters (200 ,ug of protein) of APM was added to endoperoxide dissolved in phosphate buffer and incubated at 0°C for 2 min. The thromboxane synthetase inhibitor imidazole (18) was preincubated (5 mM) with the APM (or intact platelets) for 5 min.
Platelet Radiochemical Experiments. The 14C-labeled endoperoxide ([14C]PGH2 at 100,000 cpm or [14C]PGH3 at 60,000 cpm) was incubated with washed platelets (0.4 ml) at 370C for 15 min, acidified to pH 3.5 with 2M formic acid, and extracted twice with 2 vol of ethyl acetate. The extract was dried and applied together with unlabeled PG standards (kindly supplied by The Upjohn Company) to silica gel plates. The solvent system was benzene/dioxane/acetic acid, 60:30:3 (vol/vol).
[14C]Prostacyclin Generation. The 14C-labeled endoperoxides were dissolved in 25 ,ul of phosphate buffer and incubated with 25 Al of BAM at 370C for 5 min. Acidification and extraction were carried out as described above. The solvent system (system A-9) was the organic phase from ethyl acetate/acetic acid/2,2,4-trimethylpentane/water, 110:20:50:100 (vol/vol).
Platelet Phospholipid Labeling Technique. Human blood was withdrawn into a syringe containing 1/13th vol of 77 mM EDTA and centrifuged for 10 min at 120 X g; the supernate was centrifuged at 4000 rpm for 6 min. The platelets were resuspended in 0.67 vol of albumin phosphate (33 mM, pH 6.5) containing 1 mg of glucose, 6 .6 mg of NaCl, and 5 2000 rpm for 5 min and resuspended in calcium-free KrebsHenseleit medium (pH 7.4).
Platelet Cyclic Nucleotide and ADP. Platelet cyclic AMP levels (at 60 sec) were determined by radioimmunoassay as described (19) . The concentration of ADP released from aggregated platelets was measured enzymatically as described (17) . RESULTS
Biological and Radiochemical Characterization of PGI3 and Thromboxane A3. Application of endoperoxide PGH2 or PGH3 resulted in a modest coronary relaxation and an aorta contraction ( Fig. 1; ref. 3 ). Both endoperoxides were readily converted by BAM to a powerful coronary relaxant with the concomitant loss of any intact endoperoxide as evidenced by the loss of the aorta constrictor. The enzymatically generated labile coronary relaxant is presumably PGI3 because its synthesis is blocked by the prostacyclin synthetase inhibitor 15-hydroperoxyarachidonic acid. PGH1, which lacks the z55 double bond necessary for the prostacyclin ring structure, is not converted by BAM to a coronary relaxant (3, 4, 8) . Similarly, when the endoperoxides PGH2 and PGH3 were incubated with platelet microsomes, potent labile constrictor substances were generated. This enzymatic generation was blocked by imidazole, a thromboxane synthetase inhibitor. Fig. 2 ; numbers are pg) on aggregation of human PRP.
benzene/dioxane/acetic acid solvent (Fig. 2 left) (Fig. 2 bottom left) . Radiochemical evidence of PGI3 was obtained from the incubation of [14C]PGH3 with BAM which led to the formation of a product that comigrated with 6-keto-PGF(,, (Fig. 2 right) .
15-Hydroperoxyarachidonic acid blocked formation of the triene product (Fig. 2 middle right) . 6-Keto-PGF1,, was separable from the A17-6-keto-PGF1,, (the presumed PGI3 degradation product) on AgNO3 plates (Fig. 2 bottom right) .
The striking difference between the triene and diene products became apparent from studies of platelet function. Addition of arachidonate or PGH2 (Fig. 3 top) or thromboxane A2 (1) to human PRP resulted in a rapid irreversible aggregation and ADP-release reaction. In sharp contrast, neither PGH3 nor thromboxane A3 (i.e., PGH3 plus APM) caused aggregation of PRP (Fig. 3 middle) . Furthermore, pretreatment of PRP with either PGH3 or thromboxane A3 actually inhibited subsequent aggregation by other agonists including PGH2 (Fig. 3 middle) , thromboxane A2 (Fig. 3 bottom) , ADP, and collagen (not shown).
Effect of PGH3 on Cyclic AMP Levels in PRP. Substances that increase platelet cyclic AMP levels inhibit platelet aggregation (20) (21) (22) (23) . Both PGH3 (350 ng) and thromboxane A3 increased cyclic AMP mean (±SEM) concentration (28 ± 4 and 22 ± 3 pmol of cyclic AMP per 400 ,l of PRP, respectively); PGH2 (200 ng) and thromboxane A2 caused little or no change compared to control PRP (8 ± 5; n = 4). However, these data do not preclude the possibility that the increase in cyclic AMP induced by PGH3 and thromboxane A3 might be due to conversion to PGD3 or PGE3. PGI3 (i.e., PGH3 plus BAM increased cyclic AMP to 73 i 6), PGI2 (i.e., PGH2 plus BAM increased cyclic AMP to 53 1 1), and PGH1 (300 ng increased cyclic AMP (Fig. 4 A and E (Fig. 4 B and F). Pretreatment of the arachidonate-labeled platelets with PGH3 (Fig. 4C), PGI2 (Fig. 4D) , or PGHI (100 ng) markedly decreased the release of fatty acid and abolished the thromboxane formation. There was no increase in fatty acid release over basal levels when thrombin was added to labeled platelets treated with PGH3 or PGI2 (Fig. 4 C and D) .
Competition of Eicosapentaenoate with Arachidonate for Platelet Cyclooxygenase. Unlabeled eicosapentaenoic acid and ["4C]arachidonate were mixed in varying ratios and the reaction was initiated by the addition of washed platelets. The eicosapentaenoate effectively competed with arachidonate such that a 1:1 mixture of the fatty acids resulted in a 50% inhibition of formation of thromboxane B2 and 12-hydroxyeicosatetraenoic and hydroxyheptadecatrienoic acids and block of arachidonic destruction (Fig. 5A) . On the other hand, the eicosapentaenoate was a much poorer substrate for platelet cyclooxygenase, being converted only one-eighth as efficiently as arachidonate to thromboxane (Fig. SB) . 
DISCUSSION
The synthetic pathway for the synthesis of the triene products is shown in Fig. 6 . As a result of the additional A'7-unsaturation (the only structural difference between PGH3 and PGH2) present in PGH3 or thromboxane A3, platelet adenylate cyclase is stimulated and PRP aggregation and release are inhibited (Fig. 3) (Fig. 4 C and D) . The finding that compounds that increase cyclic AMP in PRP also inhibit lipase activity agrees with results in washed platelets (17, 24) . Such agents thus would be anticipated to interfere with thrombin-induced platelet aggregation. This effect differs from that of aspirin on platelets because aspirin does not block thrombin-induced aggregation (25) .
Platelet aggregation might be suppressed by vascular synthesis of PGI3 (9) . Dietary (Fig. 5B) . However, the eicosapentaenoate effectively competes with arachidonate for platelet cyclooxygenase and lipoxygenase and thereby suppresses PGH2 and thromboxane A2 formation (Fig. 5A) 
